| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920300 | 辰光医疗 | 17.51 | -8.80% | 12.40万 | | 2.21亿 | | 300642 | 透景生命 | 22.95 | -5.40% | 17.57万 | | 4.10亿 | | 688677 | 海泰新光 | 48.50 | -5.05% | - 3.88万 | | 1.93亿 | | 688108 | 赛诺医疗 | 28.00 | -4.73% | 26.37万 | | 7.40亿 | | 688013 | 天臣医疗 | 55.66 | -3.98% | 1.92万 | | 1.10亿 | | 300289 | 利德曼 | 7.70 | -3.39% | 24.65万 | | 1.91亿 | | 301234 | 五洲医疗 | 43.80 | -2.86% | 1.29万 | | 5756.36万 | | 688068 | 热景生物 | 160.46 | -2.84% | 3.13万 | | ...

| | 业 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 603267 | 鸿远电 | 4.57 | 1.87 | 52.57 | 54.44 | 3.56 | | | 子 | | | | | | | 002174 | 游族网 | 4.76 | 4.80 | 12.99 | 13.43 | 3.39 | | | 络 | | | | | | | 301160 | 翔楼新 | 6.68 | 4.65 | 61.38 | 63.20 | 2.96 | | | 材 | | | | | | | 000820 | *ST节能 | 4.91 | 3.35 | 2.70 | 2.78 | 2.79 | | 603803 | 瑞斯康 | 3.75 | 3.76 | 9.17 | 9.41 | 2.65 | | | 达 | | | | | | | 002587 | 奥拓电 | 4.18 | 5.96 | 6.31 | 6.48 | 2.65 | | | 子 | | | | | | | 688138 | 清溢光 | 3.24 | 0.79 | 28.53 | 2 ...

截至发稿，吴兴武累计任职时间10年258天，现任基金资产总规模98.53亿元，任职期间最佳基金回报 105.25%， 任职期间最差基金回报-37.23%。 从澳华内镜十大流通股东角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 数据显示，广发基金旗下1只基金位居澳华内镜十大流通股东。广发医疗保健股票A（004851）二季度 新进十大流通股东，持有股数172.67万股，占流通股的比例为1.28%。根据测算，今日浮盈赚取约 442.03万元。 责任编辑：小浪快报 10月24日，澳华内镜涨5.3%，截至发稿，报50.86元/股，成交3786.74万元，换手率0.56%，总市值68.49 亿元。 广发医疗保健股票A（004851）成立日期2017年8月10日，最新规模52.47亿。今年以来收益19.8%，同 类排名2665/4218；近一年收益14.35%，同类排名2848/3875；成立以来收益93.64%。 资料显示，上海澳华内镜股份有限公司位于上海市闵行区光中路133弄 ...

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a significant increase in its stock price, rising by 5.45% to 49.88 CNY per share, with a total market capitalization of 6.717 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The company's main revenue sources are: endoscopy equipment (92.35%), endoscopy consumables (3.71%), endoscopy maintenance services (3.58%), and leasing income (0.35%) [1] Group 2 - Aohua Endoscopy is a significant holding in the fund managed by Agricultural Bank of China, with the Aohua Endoscopy stock representing 2.58% of the fund's net value, making it the fifth-largest holding [2] - The Agricultural Bank of China fund, named Agricultural Bank of China Specialized and New Mixed A (016305), has achieved a year-to-date return of 39.95% and ranks 1392 out of 8162 in its category [2] - The fund manager, Wei Gang, has been in charge for over 7 years, with the best fund return during his tenure being 121.47% [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy experienced a stock price increase of 5.45%, reaching 49.88 CNY per share, with a total market capitalization of 6.717 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The revenue composition of Aohua Endoscopy includes 92.35% from endoscopy equipment, 3.71% from endoscopic diagnostic consumables, 3.58% from maintenance services, and 0.35% from leasing [1] Group 2 - Among the top ten circulating shareholders of Aohua Endoscopy, ICBC Credit Suisse Fund's Aohua Medical Stock A (001717) reduced its holdings by 805,800 shares, now holding 3.0942 million shares, which is 2.3% of the circulating shares [2] - The Aohua Medical Stock A fund has achieved a year-to-date return of 26.76% and a one-year return of 20.01%, ranking 1686 out of 4218 and 2253 out of 3868 in its category, respectively [2] - The fund manager, Zhao Bei, has been in position for 10 years and 341 days, with the fund's total asset size at 16.425 billion CNY and a best return of 233% during his tenure [3]

Core Insights - As of October 17, a total of 84 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stocks with the longest streak of net buying are Kaisheng Technology and Jianyou Co., both of which have seen net buying for 10 consecutive trading days [1] - Other notable stocks with significant net buying days include Wuxi Zhenhua, Jintou Chengkai, Zhucheng Technology, Lianyu Co., Yongmaotai, Yan'ao Co., Aohua Endoscopy, and Kesi Technology [1]

资料显示，上海澳华内镜股份有限公司位于上海市闵行区光中路133弄66号，成立日期1994年10月27 日，上市日期2021年11月15日，公司主营业务涉及从事电子内窥镜设备及内窥镜诊疗手术耗材研发、生 产和销售的高新技术企业。主营业务收入构成为：内窥镜设备92.35%，内窥镜诊疗耗材3.71%，内窥镜 维修服务收入3.58%，租赁收入0.35%。 从基金十大重仓股角度 数据显示，北信瑞丰基金旗下1只基金重仓澳华内镜。北信瑞丰健康生活主题灵活配置（001056）二季 度持有股数10万股，与上期相比持股数量不变，占基金净值比例为5.48%，位居第五大重仓股。根据测 算，今日浮亏损失约7.4万元。连续4天下跌期间浮亏损失48.3万元。 10月17日，澳华内镜跌1.57%，截至发稿，报46.25元/股，成交5555.47万元，换手率0.88%，总市值 62.28亿元。澳华内镜股价已经连续4天下跌，区间累计跌幅9.46%。 北信瑞丰健康生活主题灵活配置（001056）基金经理为庞文杰。 截至发稿，庞文杰累计任职时间5年140天，现任基金资产总规模1.84亿元，任职期间最佳基金回报 44.46%， 任职期间最差基金回报- ...

Investment Rating - Industry investment rating is "Outperform the Market" (expected to outperform the CSI 300 index by more than 5% in the next 6 months) [2][24] Core Insights - The bidding environment for medical equipment remains robust, with strong demand for procurement in county-level medical communities driven by ongoing equipment update policies since 2025 [4][22] - The procurement scale for medical devices has maintained a high level, with notable monthly figures in July, August, and September 2025 being 12.8 billion, 13.1 billion, and 12.7 billion respectively, showing year-on-year growth rates of +21%, +18%, and -21% [4][13] - Major companies are benefiting significantly from the recovery in equipment update bidding, with procurement figures for September showing ultrasound at 1.646 billion (yoy +30%), CT at 1.717 billion (yoy +29%), and MRI at 1.512 billion (yoy +6%) [5][14] Summary by Sections Equipment Bidding Trends - The bidding environment for medical equipment has been consistently high, with a diverse range of procurement preferences emerging, particularly in county-level medical communities [4][9] - The procurement scale for September 2025 indicates a strong recovery, with various equipment categories showing significant year-on-year growth [5][14] Company Performance - Leading domestic companies are aligned with industry trends, with procurement figures for September showing Mindray at 0.924 billion (yoy +6%), United Imaging at 0.804 billion (yoy +18%), and Kaili at 0.163 billion (yoy +67%) [19][22] - The focus on high-end and intelligent medical devices is expected to drive performance for leading domestic enterprises such as Mindray, United Imaging, and Kaili [6][22] Future Outlook - The ongoing equipment update policies are anticipated to positively impact the bidding market, with expectations for a new round of equipment updates to stimulate demand [22] - The approval of the "Implementation Plan for Strengthening Basic Medical and Health Services" by the State Council is expected to enhance the capabilities of grassroots medical institutions, further opening up the market [22]

Summary of Key Points Core Viewpoint - Several companies are experiencing significant shareholder reductions, with multiple stakeholders planning to decrease their holdings by various percentages, indicating potential shifts in investor confidence and market dynamics [1]. Shareholder Reductions - Watson Pharmaceutical's controlling shareholder plans to reduce holdings by up to 3% [1] - Tianli Lithium Energy's New Materials Fund intends to reduce holdings by up to 3% [1] - Guangkang Biochemical's shareholder Ruihong Kaiyin No.1 plans to reduce holdings by up to 2.6757% [1] - Huayi Technology's shareholder Huang Daqing aims to reduce holdings by no more than 3% [1] - Magu Technology's shareholder Xu Longxiang plans to reduce holdings by up to 0.86% [1] - Saiwu Technology's shareholders Suzhou Suyu and Suzhou Saiying plan to collectively reduce holdings by 1.32% [1] - New Xunda's Minmetals International Trust has cumulatively reduced holdings by 1% [1] - Yandong Micro's Jingguorui has cumulatively reduced 1% of company shares [1] - Aohua Endoscopy's shareholders Junlian Xinkang and Gao Shen have cumulatively reduced 1.92% of shares [1] - Zhejiang Natural's Tiantai Ruiju Equity Investment Center has completed a 1% reduction in company shares [1] - Chunzong Technology's He Shida has cumulatively reduced 2 million shares [1] - Chiao Sensor's Li Hongqing has reduced 16 million shares through block trading [1] - Chuangye Huikang's Philips has cumulatively reduced 1.0195% of shares [1] Other Notable Events - Ruyi Group is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1] - Huangting International has terminated plans for significant asset sales and debt restructuring [1]

股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688212 证券简称：澳华内镜 公告编号：2025-064 上海澳华内镜股份有限公司 ■ 重要内容提示： ● 股东持有的基本情况 本次减持计划实施前，上海澳华内镜股份有限公司（以下简称"公司"）相关股东持股情况如下： 苏州君联欣康创业投资合伙企业（有限合伙）（以下简称"君联欣康"）持有公司股份1,030,295股，约占 公司总股本的0.77%。高燊有限公司（以下简称"高燊"）持有公司股份1,551,479股，占公司总股本的 1.15%。君联欣康与高燊构成一致行动人关系，合计持有公司股份2,581,774股，占公司总股本的 1.92%。上述股份均为公司首次公开发行前取得的股份，并于2022年11月15日起上市流通。 ● 减持计划的实施结果情况 公司于2025年7月8日在上海证券交易所网站（www.sse.com.cn）披露了《上海澳华内镜股份有限公司股 东减持股份计划公告》（公告编号：2025-053）。君联欣康和高燊拟通过集中竞价、 ...